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Xeroderma pigmentosum is an inheritable autosomal
recessive DNA repair de¢cient syndrome characterized
by a high predisposition to skin cancers. An elevated
proportion of tumors from xeroderma pigmentosum
patients harbor ultraviolet-induced mutations (CC:GG
4 TT:AA tandem transitions) of the p53 and/or the
INK4a-ARF genes. Here, we report the clinical and
molecular features of a 12 y old xeroderma pigmento-
sum patient who, in addition to severe cutaneous clini-
cal symptoms, also had three unusual tumors, a
mediastinal lymphoblastic lymphoma, an atypical ¢-
broxanthoma, and an epithelioid hemangioma. Single
strand conformation polymorphism and sequencing
analysis of the p53 and INK4a-ARF genes were carried
out in DNA from normal skin and di¡erent tumors
(four actinic keratosis, two microinvasive squamous cell
carcinomas, one basal cell carcinoma, and one atypical
¢broxanthoma) from the patient. After characterization
of the xeroderma pigmentosum C complementation
group, we found unexpectedly that this patient also car-
ried a germline mutation of the INK4a-ARF locus af-
fecting the p16INK4A reading frame. Three di¡erent
somatic mutations that all harbor the signature of ultra-
violet light (two of p16INK4A and one of p53) were also
detected in the basal cell carcinoma. We hypothesize
that the germline mutation of p16INK4A, in association
with the nucleotide excision repair defect, could explain
the patient’s unusual phenotype. Furthermore, this
study con¢rms that concomitant somatic mutations
of INK4a-ARF and p53 occur in some xeroderma
pigmentosum associated tumors, and seem to accumu-
late during tumor progression rather than the initiation
step. Key words: lymphoma/mutation/p14ARF/p16INK4A/skin
carcinogenesis/xeroderma pigmentosum. J Invest Dermatol
119:1355 ^1360, 2002
X
eroderma pigmentosum (XP) is a rare autosomal
recessive disorder associated with a germline nu-
cleotide excision repair (NER) defect (Jung, 1986).
XP patients exhibit an extreme sensitivity to sun-
light and an increased frequency of sunlight-in-
duced skin cancers, mainly basal cell carcinoma (BCC),
squamous cell carcinoma (SCC), and melanoma (Kraemer et al,
1987). Seven XP complementation groups (A^G) have been
distinguished (corresponding to mutations in distinct genes
involved in NER), as well as a variant group (XP variant), which
is de¢cient in the mutagenic polymerase Z (Masutani et al, 1999).
The XPC group is the most prevalent complementation group
in Europe, United States, and North Africa. XPC cells are
exclusively de¢cient in the NER system that corrects the ultra-
violet (UV)-induced lesions of the nontranscribed strand (‘‘global
genome repair’’), but are fully pro¢cient in the transcription
coupled repair able to remove speci¢cally UV-induced lesions of
the transcribed strand of active genes (Hanawalt, 1994). Much
progress has been made in understanding the process of skin
carcinogenesis in XP patients. p53 mutations are the most
common genetic alterations, present in more than two-thirds of
the tumors (Giglia et al, 1998). XPC knockout mice are highly
predisposed to UVB radiation-induced skin cancer (Sands et al,
1995), which carry a high proportion of p53 mutations. More
recently, a role for the INK4a-ARF locus, which maps to
chromosome 9p21 has also been demonstrated in human and
murine skin carcinogenesis. This locus gives rise to two alterna-
tive transcripts that encode two proteins, p16INK4a (exons 1a,
2, and 3) and p14ARF (exons 1b, 2, and 3), both of which are
involved in the negative control of cell proliferation (Sharpless
and DePinho, 1999). p16INK4a is a cyclin-dependent kinase inhi-
bitor that can speci¢cally inhibit progression through the
G1 phase of the replicative cycle in cells that express the retino-
blastoma protein, by blocking cyclin-dependent kinase 4
(CDK4) from phosphorylating retinoblastoma protein (Serrano
et al, 1993; Ruas and Peters, 1998). The alternative transcript,
p14ARF, in response to oncogenic signals such as c-myc, E1A, acti-
vated Ha-ras, and E2F1, speci¢cally activates the p53 pathway,
thereby inducing cell cycle arrest or apoptosis. Activation of
p14ARF results in stabilizing p53 by preventing MDM2-p53 from
undergoing ubiquitin-mediated degradation (reviewed in Sherr
andWeber, 2000).
Substantial data now implicate the INK4a-ARF locus in the de-
velopment of epithelial skin carcinoma. Deletions encompassing
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this locus are common in SCC lines and in SCC (Loughran et al,
1994).
p16ink4a is inactivated during keratinocyte immortalization
(Loughran et al, 1994; Munro et al, 1999). Moreover, nullizygous
INK4a-ARF (^/^) or speci¢cally ARF (^/^) mice are susceptible
to the development of SCC (Serrano et al, 1996; Kamijo et al,
1997). UV-induced INK4a-ARF mutations have been detected
in 12.5% of sporadic epithelial skin tumors (Sou¢r et al, 1999).
XP skin carcinomas show a higher frequency of INK4a-ARF
mutations (29% of XP associated skin tumors) that are often
multiple and associated in the same tumors with p53 mutations
(Sou¢r et al, 2000b). Little is known, however, about the timing
of INK4a-ARF mutation during the multistep process of skin
carcinogenesis. To gain insight into the role of this locus in skin
carcinogenesis, we performed a molecular analysis of skin tu-
mors, of di¡erent histologic nature or stage, arising in a single
XP patient who displays an unusual phenotype. Strikingly, we
found that this patient, in addition to belonging to the XPC
group, carries a germline mutation on the p16INK4A gene. This is
the ¢rst report of a XPC patient presenting a p16INK4a germline
mutation. Among the tumors, only the BCC carried somatic
mutations in INK4a-ARF and p53, suggesting that these modi¢-
cations occurred late in tumor progression rather than the initia-
tion stage.
MATERIALS AND METHODS
DNA repair analysis and complementation test Unexposed XP skin
biopsies were cultured to establish diploid ¢broblast lines and examined for
DNA repair level (unscheduled DNA synthesis, UDS) after UVC
irradiation as described previously (Sarasin et al, 1992). In order to con¢rm
at the molecular level the diagnosis of XP, and to determine which of the
seven XP genes involved in NER is de¢cient in our patient, we carried out
genetic complementation of his skin diploid ¢broblasts using infectious
retroviral particles expressing the wild-type XP cDNA (Carreau et al,
1995; Zeng et al, 1997). The level of DNA repair of the patient was
quanti¢ed by incorporation of tritiated thymidine (UDS) in the DNA of
his skin ¢broblasts after increasing UVC doses.
Analysis of the XPC group by western blotting analysis Protein
was extracted in 8 M urea bu¡er as described (Sybert et al, 1985).
Twenty micrograms of protein was run through a 6% acrylamide^
sodium dodecyl sulfate electrophoresis gel and then transferred on
to PVDF membrane (Amersham Pharmacia Biotech, Les Ulis, France).
Membranes were saturated overnight in phosphate-bu¡ered saline
containing 5% nonfat dried milk. The rabbit polyclonal rabbit anti-XPC
anti-serum was raised against a carboxy terminal peptide (amino acids
921^940) of the human XPC protein. Working dilution was 1/1000 in
saturation solution. As control, membrane were rehybridized using a
mouse monoclonal antibody to b-catenin (Clone 14, Transduction
Laboratories, Lexington, KY). Blots were revealed using ECL reagents
according to the manufacturer’s instructions (Amersham Pharmacia
Biotech).
Tumor samples, normal skin, and DNA extraction Eight skin
neoplasms (four actinic keratosis, two microinvasive SCC, one basal cell
carcinoma, and one atypical ¢broxanthoma) from the XP patient were
collected following surgical resection. One part was immediately fresh
frozen in liquid nitrogen and stored at ^801C. A second part was
formalin ¢xed and para⁄n embedded, and histopathologic assessment
was performed. A biopsy was also obtained of nonsun-exposed normal
skin of this XP patient. DNA was prepared from frozen samples as
previously described (Daya-Grosjean et al, 1993).
Single strand conformation polymorphism (SSCP) analysis Coding
sequence and £anking intronic sequences of exon 1a, exon 1b, and exon 2
of the INK4a-ARF gene were analyzed by polymerase chain reaction
(PCR)-SSCP. Primer sequences for exons 1a and 2 were previously
described (Sou¢r Sou¢r et al, 1999, 2000a). Exon 1bwas analyzed through
two overlapping PCR products generated by using the following primers:
P14F1 50 -TCAGGGAAGGGCGGGTGCG-30; P14R1 50 -GCCGCGGGA
TGTGAACCA-30 (PCR product: 245 bp); P14F2 50 -GCCGCGAGT
GAGGGTTTT-30; and P14R2 50 -CACCGCGGTTATCTCCTC-30 (PCR
product 257 bp). Exons 4^9 of p53 gene were ampli¢ed using the same
conditions as previously described (Sou¢r et al, 1999). Total PCR reaction
volume was 20 ml, including 50^100 ng of genomic DNA template, 30
pmol of each primer, 0.5 UI (international unit) of Taq polymerase
(Gibco-BRL) and 0.1 ml of [a33P]deoxycytidine triphosphate (Amersham).
Final MgCl2 concentration was 1.5 mM for all PCR reactions. All reactions
were supplemented with 10% dimethyl sulfoxide for optimal PCR
ampli¢cation. PCRwas processed with an annealing temperature of 601C
for the three studied exons of the INK4a-ARF gene, and 551C for exons
4^9 of p53. For SSCP, PCR products were migrated on two 0.1TBE/
Hydrolink MDE gels (FMC Bioproducts, Tebu, France), with either 8%
glycerol at room temperature or without glycerol at þ 41C. Gels were
run at 8 W, either 14 h at room temperature or 12 h at 41C, dried, and
exposed to autoradiography. The entire procedure was repeated at least
twice for each sample. Shifted bands were cut out of the gel, and
reampli¢ed using the primers mentioned above.
Sequence analysis Products from 50 ml PCR reactions from
reampli¢ed shifted bands and tumoral genomic DNAwere puri¢ed using
a Microcon 100 (Amicon, Millipore, France) and sequenced using dye-
labeled terminator on an automated sequencer 310 (Applied Biosystem,
Applera, France) according to the manufacturer’s instructions.
RESULTS
Clinical presentation A 12 y old boy from Algeria had typical
clinical features of XP (i.e., pronounced photosensibility from
the age of 3 y, erythema of photo-exposed skin, poikiloderma,
cutaneous xerosis, photophobia, and bilateral conjunctivitis).
Starting at the age of 4, multiple skin neoplasms appeared
progressively on sun-exposed areas (actinic keratosis, SCC, and
BCC).
At the age of 7, the patient presented with acute respiratory
syndrome leading to the discovery of a T cell lymphoblastic
lymphoma involving the anterior mediastinum, thymus,
pericardium, and left pleura. Blood analysis showed 40103 per
ml lymphocytes with 50% blasts. Immunotyping revealed that
these lymphocytes were CD1aþ , CD4þ, CD7þ, CD8þ,
HLADRþ , and weakly CD3þ. All B markers were negative. A
bone marrow analysis showed low cell counts without blasts.
Highly carcinogenic drugs (i.e., antracyclins, alkyling agents,
or cyclophosphamide) were considered contraindicated in
this patient and a milder treatment regimen, including
corticosteroids, Aracytin and Purinethol was started and well
tolerated. The patient did not receive radiotherapy. After the
initiation cure followed by several consolidation cures, the
patient was considered in complete remission and has been
stable since 1997.
At the age of 10, this patient had two unusual tumors: an
atypical ¢broxanthoma localized on the left ear and an
epithelioid hemangioma of the neck that were surgically
removed.
DNA repair de¢ciency A near to wild-type recovery of UV
cell survival was observed solely after transduction of the XPC
cDNA (Fig 1). In contrast, transduction of other XP cDNA (as
exempli¢ed in Fig 2 using the XPD cDNA) did not result in
the recovery of UV cell survival (Fig 1). The level of repair
defect has been quanti¢ed by UDS after UVC irradiation of the
diploid ¢broblasts of the patient, as previously described (Sarasin
et al, 1992). As shown in Fig 2, the UDS level is only 10^15% of
our control normal ¢broblast lines and similar to a control XPC
¢broblast line.
This allowed us to conclude that our patient belongs to the
XPC group. The patient’s ¢broblasts complemented by the wild-
type XPC gene exhibit normal UDS (not shown).
Recovery of XPC protein expression in stable XPC-
transduced XPC keratinocytes Our complementation data
(Figs 1 and 2) strongly supported the appartenance of XP208VI
to the XPC group. To support further these functional
observations, protein extracts were prepared from WT (198VI),
XP208VI, and XPC-transduced XP208VI ¢broblasts. A
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keratinocyte strain, XP148VI, known to express a truncated XPC
protein and its XPC-transduced counterpart (Arnaudeau
et al, 2002), were used as control. Protein were processed
for western blot analysis using the anti-XPC rabbit anti-serum
(Fig 3). The apparently full length XPC protein (125 kDa) was
detected in a WT control cell (198VI). In contrast, the XPC
protein was neither detected in extracts from XP208VI nor, as
already shown, in extracts from the XPC control cell strain
XP148VI (Arnaudeau et al, 2002). In both XP cell strains
(XP208VI, XP148VI) the absence of XPC protein detec-
tion indicated the absence of the XPC epitope recognized by
the anti-serum raised against the carboxyterminal part of the
XPC protein. On the contrary, XPC-transduced cells,
i.e., XP208VIþXPC and XP148VIþXPC, expression of the
apparently full length XPC protein was recovered as compared
with that detected from WT 198VI extracts. As in most other
XPC patients studied to date (Chavanne et al, 2000), the absence
of the full length XPC protein in XP208VI cells could
be considered as a de¢nitive assignment to the XPC
complementation group.
Mutational analysis of the INK4a-ARF locus SSCP analysis
revealed abnormal bands for exon 1a only in one tumor (sample
7), the BCC. In exon 2, a common abnormal migration pattern
was observed from all DNA analyzed (tumoral, normal skin, and
normal ¢broblast cell line), with an additional bandshift in tumor
sample 7, the BCC. No abnormal band was seen for exon 1b
of p14ARF. DNA sequencing of abnormal bands revealed
three mutations located within the cDNA sequence (Table I and
Fig 4). One was characterized as a germline mutation, as it was
present in DNA from all tumoral samples as well as from the
patient’s normal skin and ¢broblast cell line. This germline
mutation was a G4T transversion resulting in a mis-sense
mutation in the p16INK4a reading frame (Ala127Ser). In contrast,
this mutation had no consequence on p14ARF, as it lies outside
of its coding sequence (Table I). The two other alterations
are somatic mutations of the BCC (tumor 7), which are
characteristic UV-induced mutations occurring at dipyrimidic
sites. One was a C:G4T:A transition located in the 50 untranslated
sequence of p16INK4a cDNA, possibly corresponding to a regulatory
mutation. The second was a tandem CC:GG4TT:AA transition
and corresponds to a known mutational hotspot in XP-associated
skin tumors (Sou¢r et al, 2000b). This mutation also a¡ects the
p14ARF reading frame, at a codon conserved between mouse and
human cDNA.The nucleotide composition of this codon (CCC)
makes it a prime target for mutagenesis by UV.
Mutational analysis of the p53 gene SSCP analysis re-
vealed a unique bandshift in exon 7 of the p53 gene, in BCC 7,
corresponding to a tandem CC:GG4TT:AA transition
that resulted in a mis-sense mutation at codon 248 of the p53
Figure1. Genetic complementation and UV cell survival of the
patient’s skin ¢broblasts. Relative cell survival is indicated as the ratio
of the number of colonies in irradiated to nonirradiated cells. UVC doses
are indicated. Note that transduction of the patient’s ¢broblasts (XP208 VI)
by the XPC cDNA (XP208VI+LXPCSN) but not by the XPD cDNA
(XP208 VI+LXPDSN) leads to near normal UVcell survival (198VI), thus
assigning the patient to the XP complementation group C.
Figure 2. Severe alteration of DNA repair capacity of the patient’s
¢broblasts revealed by UDS after UVB irradiation. Number of auto-
radiographic grains over nuclei of the patient’s and control ¢broblasts were
plotted as a function of the UVC dose. Note that the patient’s ¢broblasts
(XP208 VI) and a control XPC (XP202 VI) strain reach a maximum of
10^15% of values obtained with normal cells (198VI).
Figure 3. Absence of the full length XPC protein in XP208VI
patient cells.Western blot analysis was carried out using protein extracts
from XP208VI cells before XP208VI (XPC) and after retroviral transduc-
tion (XP208VI+XPC). 198VI (WT control) is a normal ¢broblast strain.
XP148VI (XPC) is a keratinocyte strain known to belong to the XPC com-
plementation group. XP148VI+XPC are XP148VI cells following retroviral
transduction of XPC (Arnaudeau et al, 2002). Note that XPC is not de-
tected in extracts from XP148VI and XP208VI (studied patient), whereas
the full length protein is re-expressed in transduced cells as in XP198 WT
control. The same membrane was stripped and then rehybridized using
anti-b-catenin monoclonal to control that similar amounts of protein were
present in this area of the membrane. The star indicates a nonspeci¢c band
found in any condition.
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gene (Table I). This mutation is a p53 hotspot found
predominantly in skin cancers from XP patients (Beroud and
Soussi, 1998).
DISCUSSION
To gain insight into the role of the INK4a-ARF and p53 genes in
XP skin carcinogenesis, we performed a molecular analysis of the
INK4a-ARF and p53 genes in skin tumors with di¡erent charac-
teristics and stages arising in a single XP patient that displayed
a particularly severe phenotype.
Remarkably, our XP patient developed three unusual
tumors. To the best of our knowledge, non-Hodgkin lympho-
blastic mediastinal lymphoma has never been described in a XP
patient (Kraemer et al, 1987). Epithelioid hemangioendothelioma
arising in the skin is extremely rare, and was also not pre-
viously described in XP patients (Kraemer et al, 1987). Atypical
¢broxanthoma is a pleomorphic tumor usually classi¢ed as a
distinct subtype of malignant ¢brous histiocytoma that usually
occurs on actinically damaged skin in the elderly, only rarely
reported in XP patients (Patterson and Jordan, 1987; Dilek et al,
2000).
Unexpectedly, this patient was found to carry a p16INK4a
germline mutation (Ala127Ser) characterized by its presence in
normal skin and a ¢broblast cell line as well as in all the tumor
samples analyzed. Several arguments convey toward a pathogenic
e¡ect of this mutation. First, this mutation is located in the fourth
ankyrin domain of the protein, a domain crucial in p16INK4a
function. Secondly, this mutation was reported as a germline
mutation in patients that developed di¡erent types of cancer:
melanoma (Gruis et al, 1995); lung cancer (Okamoto et al, 1994);
and primary human esophageal tumors (Zhou et al, 1994; Suzuki
et al, 1995). Furthermore, in Suzuki et al (1995), this mutation was
associated with loss of the normal remaining allele in the
esophageal tumor. Ala127Ser was also characterized as an ac-
quired somatic mutation in a SCC of the bladder (Gonzalez-
Zulueta et al, 1995). Some functional studies did not ¢nd any ef-
fect of this variant on CDK4 binding (Koh et al, 1995; Ruas et al,
1999). A recent study, however, reported that testing of p16INK4a
interactions with CDK in protein binding assays is an unreliable
predictor of mutant p16INK4a function in cells (Becker et al, 2001).
Indeed, in one study, this Ala127Ser allele was intermediate in its
ability to cause growth cell arrest (Koh et al, 1995). Altogether,
these data indicate that Ala127Ser may be a p16INK4a germline
mutation rather than a polymorphism. In addition, our hypoth-
esis that abrogation of p16INK4a could probably have contributed
to the patient’s particularly severe phenotype is reinforced by pre-
vious observations. First, germline defects of the INK4a-ARF lo-
cus might predispose to hematologic malignancies: (i) a germline
mutation of p16INK4a that was recently shown to predispose a
patient to multiple myeloma, which is another hematopoietic
disorder (Dilworth et al, 2000), and (ii) mice nullizygous or
heterozygous for the INK4a-ARF locus are highly prone to
lymphoid malignancies as well as reticulosarcomas (Kamijo et al,
1997). Second, inactivation of the INK4a-ARF locus occurs
commonly in human lymphoid disorders (Ruas and Peters,
1998) as well as in malignant ¢brous histiocytoma, a tumor his-
tologically related to atypical ¢broxanthoma (Brinck et al, 1998;
Simons et al, 2000).
Three somatic mutations were also detected, one in the p53
gene, and two in the INK4a-ARF gene, that were all found in
only one of eight (12.5%) skin tumors.This is an overall low mu-
tation frequency. This contrasts with the high frequency of p53
Figure 4. Germline and somatic mutations of the INK4a-ARF
gene. Arrows above the automated sequence traces indicate the positions
of mutated bases. The wild-type sequence and the nucleotide changes, and
the coding e¡ect of the changes on p16INK4a and p14ARF are listed inTable I.
The sequence is shown 50-30 for the coding strand. The sequence is writ-
ten 50-30 for the coding strand; the mutated base is written in upper case
letters. The text in bold indicates nucleotide and amino acid changes. The
text in italics, indicates the germline p16INK4a mutation. Mutations indi-
cated by an asterisk are predicted to be UVB-induced mutations. Muta-
tions on conserved residues of p14ARF are underlined.
Table I. p16INK4a, p14ARF, and p53 mutations characterized in XPC skin epithelial tumors
Samples
analysed
Histological
Diagnosis
INK4a-ARF Sequence
change
p16INK4A
aa change
p14INK4A
aa change
p53
sequence change
p53
aa change Tumor
Skin tumors
1 microinvasive SCC tcGca4tcTca Ala127Ser lip
2 AK tcGca4tcTca Ala127Ser forehead
3 AK tcGca4tcTca Ala127Ser ear
4 AK tcGca4tcTca Ala127Ser vertex
5 microinvasive SCCþAK tcGca4tcTca Ala127Ser vertex
6 AK tcGca4tcTca Ala127Ser vertex
7 nodular BCC tcGca4tcTca Ala127Ser aaC
Cgg4aaTTgg
Asn247Asn/
Arg248Trp
right eye
gcCCgt4gcTTgt Proll4Leu Ala128 Ala/
Arg129Cys
gtGgg4gttg (69 atg) 50UTR/none
8 Atpical¢broxanthoma tcGca4tcTca Ala127Ser ear
Normal skin tcGca4tcTca Ala127Ser
Fibroblastline tcGca4tcTca Ala127Ser
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mutations detected in normal skin, precancerous, and cancer le-
sions arising in XP patients (Williams et al, 1998). This discre-
pancy may have several explanations. First, it should be noted
that all but one tumor (85%) were small lesions; i.e., either
precancerous lesions (actinic keratosis in 57% of cases) or
microinvasive SCC (in 28% of cases). In line with this, in a pre-
vious study, XP skin tumors less than 8 mm in diameter were
shown to harbor a signi¢cantly lower frequency of p53 mutation
than larger tumors from the same XP patients (Matsumura et al,
1995). Additionally, our tumor was not microdissected and this
could account for a lower sensitivity of mutation detection.
Finally, in our particular case, the presence of a p16INK4a germline
mutation could have decreased the need for additional p53
mutations.
Moreover, we previously detected INK4a-ARF mutations in
only one of six sporadic SCC of early grade (Bowen diseases or
actinic keratosis; (Sou¢r et al, 1999), which correlate with our pre-
sent results and seem to signify that such mutations occur in the
late stage of tumor development.
All three mutations detected in the BCC were characteristic of
UV-induced lesions, occurring at dipyrimidinic sites, and located
in two cases on the nontranscribed strand of the gene. The third
mutation is due to an unrepaired DNA lesion that lies outside the
transcribed sequence and therefore is not preferentially repaired.
This mutational pattern is highly characteristic of XPC patients,
pro¢cient in preferential repair of active transcribed genes (Giglia
et al, 1998; Sou¢r et al, 2000b). It is important to note that muta-
tions of the three genes (p53, p16INK4a, and p14ARF) occurred
in the same tumor. This association was previously found in XP
tumors (Sou¢r et al, 2000b), and is probably related to the high
genetic instability linked to the DNA repair defect in these pa-
tients. The accumulation of unrepaired mutations leads to the
preferential selection of tumoral clones sharing inactivation of
multiple tumor suppressor pathways.
In conclusion, we show for the ¢rst time that the coexistence
of germline inactivation of a DNA repair gene and a cell cycle
regulator gene that may have acted in concert to generate cancer
proneness in a patient.
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